Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
Operations Officer effective June 1, 2026, and Janice Kapty as SVP of Corporate Strategy and Project Leadership to guide clinical, operational and portfolio execution. An interesting aspect of these appointments is how the combined financial, clinical operations and portfolio expertise is being aligned around advancing vopimetostat and other pipeline candidates, including TNG456, through complex global development pathways. We'll now examine how this strengthened clinical development and operations leadership bench could shape Tango Therapeutics' investment narrative for investors. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it . Find the list for free. What Is Tango Therapeutics' Investment Narrative? To own Tango today, you have to believe its precision oncology pipeline, led by vopimetostat and TNG456, can justify a high valuation despite ongoing losses and forecast unprofitability.
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatGlobeNewswire
- Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by B. Riley Financial, Inc..MarketBeat
- Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (TNGX) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge [Yahoo! Finance]Yahoo! Finance
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- TNGX's page on the SEC website